(Sharecast News) - AstraZeneca announced contrasting results from two phase three trials involving its immunotherapy drug 'Imfinzi', or durvalumab, on Tuesday.
The FTSE 100 pharmaceuticals giant said the ADJUVANT BR.31 trial, sponsored by the Canadian Cancer Trials Group (CCTG), investigated Imfinzi in early-stage non-small cell lung cancer (NSCLC).

It said...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE